Thymic Malignancy-Updates in Staging and Management

Jesse M P Rappaport; James Huang; Usman Ahmad

doi:10.1016/j.soc.2020.06.010

Thymic Malignancy-Updates in Staging and Management

Surg Oncol Clin N Am. 2020 Oct;29(4):581-601. doi: 10.1016/j.soc.2020.06.010. Epub 2020 Aug 11.

Authors

Jesse M P Rappaport¹, James Huang², Usman Ahmad³

Affiliations

¹ Department of Cardiothoracic Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
² Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
³ Department of Cardiothoracic Surgery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA; Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA; Transplant Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: AHMADU@ccf.org.

PMID: 32883460
DOI: 10.1016/j.soc.2020.06.010

Abstract

Thymomas are relatively indolent tumors that present with locally advanced disease in 30% of the patients. Thymic carcinoma is a more aggressive histology with shorter disease-free and overall survival. Early-stage tumors are managed best with complete resection. Multimodal therapy is the standard of care for locally advanced tumors and neoadjuvant therapy may help improve respectability. Stage and complete resection are the strongest prognostic factors for long-term survival. Based on early experience, targeted and immunotherapies have shown limited promise in advanced disease.

Keywords: Chemoradiation; Chemotherapy; Multimodal therapy; Neoadjuvant; Thymic carcinoma; Thymoma.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Combined Modality Therapy
Disease Management
Humans
Neoplasm Staging / standards*
Thymus Neoplasms / classification
Thymus Neoplasms / pathology*
Thymus Neoplasms / therapy*